NASDAQ
Acumen Pharmaceuticals, Inc. (ABOS) reported revenue of $0 and net income of $-121,335,000 for FY 2025, with a net profit margin of 0%. Revenue represents total sales while net income is the profit remaining after all expenses. The relationship between them reflects overall profitability.
No price data available for this timeframe.